In partnership with Grail, the Galleri® multi-cancer early detection test detects cancer signals across 50+ types of cancer as early as stage one. Test annually and stay vigilant for early warning signs. *This add-on test is available for an additional cost and is not included in the $499 membership.

Types of cancer tested: Adrenal Cortical Carcinoma, Ampulla of Vater, Anus, Appendix, Carcinoma, Bile Ducts, Bladder, Urinary, Bone, Breast, Cervix, Colon and Rectum, Esophagus and Esophagogastric Junction, Gallbladder, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Neoplasms, Kidney, Larynx, Leukemia, Liver, Lung, Lymphoma (Hodgkin and Non-Hodgkin), Melanoma of the Skin, Merkel Cell Carcinoma, Mesothelioma, Nasal Cavity and Paranasal Sinuses, Nasopharynx, Neuroendocrine Tumors, Oral Cavity, Oropharynx, Ovary, Fallopian Tube and Primary Peritoneum, Pancreas, Penis, Plasma Cell Myeloma and Plasma Cell Disorders, Prostate, Small Intestine, Soft Tissue Sarcoma, Stomach, Testis, Ureter, Renal Pelvis, Uterus, Vagina, and Vulva.

Measuring one's PSA screens for tumors and/or monitors preexisting prostate cancer. On its own, it can not be used to diagnose cancer. Rather, this test and one's total PSA reveals the health of your prostate and acts as a signal if something is wrong.

This percentage helps determine the risk of prostate cancer and is often referred to if a doctor is deciding whether or not to conduct a biopsy. The percentage is calculated by dividing free PSA by total PSA and multiplying it by 100%.

Measuring one's PSA screens for tumors and/or monitors preexisting prostate cancer. On its own, it can not be used to diagnose cancer. Rather, this test and one's free PSA reveals the health of your prostate and acts as a signal if something is wrong.